Mike Ward
Global Head of Thought Leadership at Clarivate
Commentating on issues consequential to pharma, biotech, healthcare & medtech stakeholders
Articles
-
Jan 9, 2025 |
insights.citeline.com | Mike Ward
Seventure Reaffirms Microbiome Confidence With New €200m Fund06 Mar 2019 • By Mike WardWith its first microbiome fund completing its investment period, French venture capitalist Seventure Partners has raised more than €100m of a €200m target for its second microbiome-focused fund. Exponential increase in microbiome potential
-
Dec 10, 2024 |
insights.citeline.com | Mike Ward
Lundbeck Looks For Assets Across Value Chain To Ride Storm08 Feb 2019 • By Mike WardWhile the Danish pharma unveiled its best ever financial results, recently installed ceo Deborah Dunsire confirms to Scrip that the company needs to bolster its pipeline and portfolio with assets in all phases of the value chain. Lundbeck Maintains Focus On Brain Diseases • Source: Shutterstock
-
Oct 17, 2024 |
clarivate.com | Mike Ward |Sonia Lopez
In-licensing and acquisitions are fast tracks for pharmaceutical companies to access groundbreaking technologies and assets that will drive the next generation of transformative patient treatments. Dealmaking is not a trivial process. Audience members during the recent Clarivate webinar Emerging Deal Trends in Biotech and Pharma identified three of the biggest challenges they face when securing deals.
-
Sep 17, 2024 |
clarivate.com | Mike Ward |Varun Saxena
The biotech industry has experienced a rollercoaster of financing and dealmaking trends over the past few years. From the record-breaking heights of the COVID-19 era to the recent slowdown in 2023, signs of resilience and recovery are beginning to emerge. In the first half of 2024, the biotech industry is witnessing early signs of a rebound in financing and dealmaking activities. However, it may not reach the peak levels seen during the height of the pandemic.
-
Sep 13, 2024 |
shouldiseeit.net | Mike Ward |Christian Tafdrup |Mads Tafdrup
R Running Time: 110 mins SHOULD I SEE IT? Protect James McAvoy at all costs. As a diabolical, unhinged villain - there may be no one better at this right now. Entertaining and quite witty for a long duration of the film’s run time, with an uneasy tension building the entire time, Speak No Evil is one of 2024’s biggest surprises. The film alters the 2022 Danish original film’s conclusion. For mainstream American audiences, this will not be a complaint.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 5K
- Tweets
- 13K
- DMs Open
- No
Working on my annual #biopharma and #medtech “Winners & Losers” presentation for the Genesis 2024 conference. Happy to receive nominations for entry into the list - list them here or send to [email protected]
Just to let my followers here know, like many others, I will be transitioning to Blue Sky - my handle will be @BioPharmaMike.bsky.social #biotech #biopharma #medtech
First #USFDA NDA submission for any psychedelic-assisted therapy as MAPS PBC seeks approval for an #MDMA-assisted therapy for #PTSD; #NDA includes two Phase 3 trials (MAPP1 and MAPP2) that both met primary and secondary endpoints #pharma #biotech
